American Vanguard lowers 2025 EBITDA and revenue targets while advancing cost containment and inventory management

Earnings Call Insights: American Vanguard Corporation (AVD) Q1 2025

MANAGEMENT VIEW

* CEO Douglas A. Kaye opened the call noting that "the year 2024 was one of great change at American Vanguard and was then capped off by a prolonged financial close and audit that delayed our Form 10-K and consequently, the 10-Q." He emphasized that audited numbers were "substantially similar to the unaudited results" and highlighted progress in controllable areas: "our operating expenses dropped by $5 million and net trade working capital was reduced $86 million, both in comparison to last year."
* Kaye reported, "channel inventories in the U.S. are at historic lows", and stated, "we are seeing a stronger second quarter and expect the remainder of 2025 will be solid." However, he also noted, "The first quarter of 2025 was somewhat weaker than we had initially anticipated" due to ongoing destocking, competitive program adjustments, absence of a previously canceled product, weakness in the Mexican agave market, and drought in Australia.
* Metam sales were up 14% versus last year and Thimet sales rose 17%, reflecting positive product performance in targeted segments.
* Kaye addressed guidance: "we are decreasing our full year adjusted EBITDA target range to $40 million to $44 million from $45 million to $52 million, and we are adjusting our revenue estimate to $535 million to $545 million."
* CFO David T. Johnson acknowledged late filings and internal control matters at the Australian subsidiary, but stated, "as you may recall, we have published unaudited year-end financial information in March. Now that we have filed our financials, we have been able to report only minor changes from our prior [indiscernible]." Johnson reported, "Our first quarter 2025 revenue was $116 million, a decrease of 14% as compared to the first quarter of 2024."
* Johnson added, "Gross profit margin declined to 26% during the quarter as compared to 31% last year."

OUTLOOK

* Management lowered full-year 2025 adjusted EBITDA guidance to $40 million to $44 million and revenue guidance to $535 million to $545 million, citing a "weak first quarter and a market that is only beginning to recover."
* Kaye said, "we are beginning to see early stages of a recovery, we do not want to forecast an overly optimistic outlook at this juncture."
* Johnson expects CapEx to be in the $8 million to $9 million range for 2025 and "virtually all free cash flow to be allocated towards debt paydown."

FINANCIAL RESULTS

* First quarter 2025 revenue was $116 million, down 14% year-over-year, as reported by Johnson.
* Adjusted EBITDA for the quarter was $3 million compared to $15.5 million in the prior year's first quarter, with the prior year benefitting from specific one-time items.
* Gross profit margin declined to 26% from 31% in Q1 2024.
* Operating expenses were down approximately $5 million year-over-year, excluding transformation expenses and a one-time benefit in Q1 2024.
* Working capital ended $86 million lower than the prior year, and debt was approximately $20 million (14%) lower year-over-year.

Q&A

* Benjamin David Klieve, Lake Street Capital, asked about the cadence of year-over-year top line performance and the impact of destocking. Kaye responded that "levels that we saw at the beginning of the year in the channel suggested that the inventories had been destocked. But it just continued through all the way to April... And then as we see now, we do see positive trends in May and June related to our sales."
* Klieve requested detail on the first quarter EBITDA and revenue contributions from Dacthal. Kaye replied, "It's top line $6 million and margin 3.5." Klieve clarified this was on a gross margin basis, which Kaye confirmed.
* Klieve asked about the balance of the portfolio. Kaye said it was "effectively flat with the highlights being on the other side, metam sodium and Thimet."
* Klieve inquired about seasonality expectations. Kaye stated, "the second half of the year is always the strongest for us."
* Klieve asked about implications of acreage shifts. Kaye explained, "Our portfolio does lend itself to corn acres with our corn soil insecticides."
* Klieve queried cash tax expectations. Johnson said, "I think we're in the $4 million or $5 million range."
* Wayne Pinsent, Gabelli Funds, asked about margin targets. Kaye stated, "nothing's changed in my outlook of the company and the goal of 15% EBITDA margin over the long term."
* Pinsent asked about improvement in 2026. Kaye indicated, "We are projecting growth in 2026 in our 5-year plan ... as we rightsize and go through the transformation process on our commercial activities."
* Rosemarie Morbelli, Gabelli Funds, requested details on pricing and generics. Kaye explained, "There was some very unusual activity that took place that's not normal for end of quarter-type situation" and described discounting due to low customer willingness to take on inventory.

SENTIMENT ANALYSIS

* Analysts pressed on destocking trends, product-specific headwinds, and margin trajectory, reflecting a slightly negative to neutral tone and seeking clarity on recovery and confidence in future targets.
* Management maintained a cautious but constructive tone in prepared remarks, acknowledging challenges but repeatedly stressing confidence in transformation efforts and long-term targets. Phrases like "we are beginning to see the benefits of our transformation efforts" were balanced by caution: "I don't want to sound too optimistic as the level of economic uncertainty remains extremely high."
* Compared to the previous quarter, analysts' tone shifted towards more granular questions on headwinds and near-term recovery, while management became more explicit about cost containment and guidance adjustments, reflecting a more defensive but transparent posture.

QUARTER-OVER-QUARTER COMPARISON

* Guidance was lowered from $45 million-$52 million EBITDA and $565 million-$585 million revenue in Q4 2024 to $40 million-$44 million EBITDA and $535 million-$545 million revenue in Q1 2025.
* Management focus shifted from emphasizing transformation and complexity reduction to spotlighting cost containment and working capital management.
* Analysts' focus moved from structural changes and transformation costs to immediate product, margin, and destocking impacts.
* Management’s confidence in achieving long-term margin targets remained, but short-term caution increased.
* Key metrics including revenue, EBITDA, and gross margin all declined sequentially, with management attributing the drop primarily to destocking, product portfolio changes, and external market conditions.

RISKS AND CONCERNS

* Ongoing destocking in the channel and delayed inventory replenishment constrained top-line performance.
* Pricing pressure and aggressive competitor incentives impacted gross profit margin.
* Specific geographic headwinds included weakness in the Mexican agave market and drought in Australia.
* Internal control weaknesses at the Australian subsidiary and ERP implementation challenges were acknowledged by management, with remediation plans underway.
* Management is prioritizing cost reduction, working capital efficiency, and flexible refinancing to address higher expected interest rates.
* Tariff uncertainty and global trade dynamics continue to cloud the outlook, with management monitoring the situation closely.

FINAL TAKEAWAY

American Vanguard’s first quarter of 2025 reflected ongoing challenges from market destocking, competitive pricing, and regional headwinds, prompting a reduction in full-year revenue and EBITDA guidance. Management underscored progress in cost containment and working capital improvements, as well as the resilience of key products like metam and Thimet. While near-term caution persists amid economic uncertainty and delayed recovery, the company remains focused on transformation, operational efficiency, and positioning for a cyclical upturn as inventory levels normalize and customer activity increases.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/avd/earnings/transcripts]

MORE ON AMERICAN VANGUARD

* American Vanguard Corporation (AVD) Q1 2025 Earnings Call Transcript [https://seekingalpha.com/article/4793060-american-vanguard-corporation-avd-q1-2025-earnings-call-transcript]
* American Vanguard Corporation 2025 Q1 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4793059-american-vanguard-corporation-2025-q1-results-earnings-call-presentation]
* American Vanguard Corporation (AVD) Q4 2024 Earnings Call Transcript [https://seekingalpha.com/article/4767711-american-vanguard-corporation-avd-q4-2024-earnings-call-transcript]
* American Vanguard receives NYSE notice regarding delayed 10-K filing [https://seekingalpha.com/news/4428869-american-vanguard-receives-nyse-notice-regarding-delayed-10-k-filing]
* Seeking Alpha’s Quant Rating on American Vanguard [https://seekingalpha.com/symbol/AVD/ratings/quant-ratings]